NCT06461689 - Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 28, 2025

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

177Lu-PSMA-617

All patients treated with 177Lu-PSMA had a post-therapy 68Ga-PSMA PET scan and a post-therapy 177Lu-PSMA-617 SPECT/CT scan. These scans are available in the CHRU PACS, and patients are informed that their data may be used for research purposes, via posters in the nuclear medicine department or via the welcome booklet,

Trial Locations (1)

54511

CHRU de NANCY, Vandœuvre-lès-Nancy

All Listed Sponsors

lead

Central Hospital, Nancy, France

OTHER